Weight Management
Amylin & Weight Management | CareSync™ Psych
Peptide Therapy
Amylin and Weight Management: A Mental Health Perspective
CagriSema, an investigational combination of the amylin analogue cagrilintide and the GLP-1 medication semaglutide.
Another emerging approach combines eloralintide, an investigational amylin receptor agonist, with tirzepatide, which targets GIP and GLP-1 receptors.
CareSync™ Psych · Research & Education
Weight Management, Mental Health & the Next Wave of Treatment
A psychiatric perspective on amylin and emerging peptide medications
Research update · October 3, 2026
Weight changes can feel especially frustrating when you are already working hard to manage your mental health. Sleep, stress, and certain medications used for depression or psychotic disorders can contribute to weight gain. These concerns deserve a thoughtful conversation, without blame. [8]
New research into amylin offers another perspective on the biology of appetite—and on how future treatments may expand our options.
Recent scientific reviews describe how amylin-based medications could expand treatment options for obesity and type 2 diabetes. The innovation is in working with the biological signals that influence appetite, fullness, and blood sugar. [1–4]
What is amylin?
Amylin is a peptide hormone released by the pancreas alongside insulin. After a meal, it helps signal fullness, slows the movement of food from the stomach, and helps regulate blood sugar by reducing inappropriate glucagon release.
Scientists are developing longer-acting amylin analogues—medications designed to mimic some of these effects—to support weight management. They act through pathways that differ from those targeted by GLP-1 medications. [1–2]
Why are combination treatments getting attention?
Appetite and metabolism involve several interacting signals. Researchers are exploring whether targeting complementary pathways can produce greater benefits than targeting one pathway alone.
One example is CagriSema, an investigational combination of the amylin analogue cagrilintide and the GLP-1 medication semaglutide. Clinical studies have demonstrated substantial weight loss, and an application for U.S. approval has been submitted. An application is a step in the review process; it does not mean a medication is already approved or available for routine prescribing. [5]
Another emerging approach combines eloralintide, an investigational amylin receptor agonist, with tirzepatide, which targets GIP and GLP-1 receptors. In September 2026, Lilly reported that this combination produced greater weight loss than tirzepatide alone in a phase 2b study involving adults with overweight or obesity and type 2 diabetes. Gastrointestinal side effects and treatment discontinuation were also concerns. Larger trials are needed to clarify its benefits and tolerability. [6]
Promising research, realistic expectations.
Study results are averages—not predictions of an individual person’s outcome. Investigational treatments require further evaluation and regulatory review.
What does “peptide therapy” actually mean?
Peptides are short chains of amino acids. Some act as signals within the body, and some medications are designed to mimic those signals.
The word peptide alone does not tell us whether a product is effective, safe, or approved. Each medication needs its own evidence. Established prescription treatments, medications being studied in clinical trials, and products marketed online as “research peptides” have very different levels of oversight.
The FDA specifically warns against unapproved weight-loss products and states that cagrilintide and retatrutide cannot be used in compounding under federal law. Products labeled “for research purposes” should not be treated as patient medications. [7]
Why this matters in psychiatric care
At CareSync™ Psych, medication conversations include how treatment affects your daily life, including appetite, sleep, energy, and weight. If weight changes begin after a medication change, bring that concern to your prescriber. We can review the timing, benefits, side effects, and possible options together. Do not stop psychiatric medication on your own.
Appetite biology and emotional eating are related, but they are different parts of the picture. Medication research does not replace attention to stress, coping patterns, body image, or a history of disordered eating. Emerging amylin treatments should not be presented as established treatments for depression, anxiety, or eating disorders.
A plan that supports physical and emotional health
A thoughtful evaluation may include your current medications, weight trajectory, sleep, eating patterns, medical history, and metabolic health. We also want to understand what progress means to you—whether that is more energy, fewer medication-related concerns, a healthier relationship with food, or improved physical health.
For patients with a history of restrictive eating, binge eating, or purging, those experiences should be discussed before considering appetite-suppressing treatment. Your mental health and nutritional needs remain central to the plan.
Let’s talk about the whole picture
If appetite changes or weight concerns are affecting your well-being, schedule a visit with CareSync™ Psych. Together, we can review your treatment and discuss appropriate next steps, including coordination with medical or nutrition care when needed.
Visit CareSync™ PsychCareSync™ Psych — Educational Disclaimer
Posts published by CareSync™ Psych are for educational and informational purposes only. They do not constitute medical advice, an individualized treatment recommendation, or an endorsement of any medication, peptide, product, procedure, or therapy discussed. Mention of a treatment does not imply that it is approved, appropriate for you, or offered by CareSync™ Psych. This content does not replace an evaluation by a qualified healthcare professional or establish a provider–patient relationship. Decisions about your healthcare, including starting, stopping, or changing medications or treatments, should be made collaboratively with your physician and treating healthcare team. Do not make treatment changes based solely on these posts. Healthcare evidence, regulatory status, and recommendations may change as new information becomes available.
References & further reading
- Lutz, T. A. (2026). Amylin analogues as a novel perspective in anti-obesity therapy. British Journal of Pharmacology.
- Secher, A., Lutz, T. A., & Raun, K. (2026). The story of amylin: from physiology to therapy. Nature Metabolism, 8, 299–312.
- Koleva, N., Dinkov, B., & Stavreva, G. (2026). Amylin and amylin analogs—future therapeutic strategies for the treatment of type 2 diabetes and obesity. Journal of IMAB, 32(2), 6901–6907.
- Le Foll, C., & Lutz, T. A. (2026). Amylin: A multi-functional pancreatic hormone—a review. Diabetes, Obesity and Metabolism, 28, 27–41.
- Novo Nordisk. CagriSema FDA submission for weight management. Manufacturer announcement.
- Eli Lilly and Company (September 30, 2026). EloraTZP phase 2b results. Manufacturer-reported study findings.
- U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss.
- National Institute of Diabetes and Digestive and Kidney Diseases. Factors affecting weight & health.
